within Pharmacolibrary.Drugs.ATC.L;

model L01FF09
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.1166666666666665e-06,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00316,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00283,
    k12             = 0.297,
    k21             = 0.297
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FF09</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tislelizumab is a humanized IgG4 monoclonal antibody that binds to programmed cell death protein 1 (PD-1) and blocks its interaction with PD-L1 and PD-L2, thus enhancing T-cell-mediated immune responses against tumor cells. It is used in cancer immunotherapy and is approved for the treatment of certain cancers, including classical Hodgkin lymphoma and urothelial carcinoma in some countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult cancer patients, both sexes, majority with solid tumors, administered intravenous dose.</p><h4>References</h4><ol><li><p>Shen, L, et al., &amp; Wu, YL (2020). Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. <i>Journal for immunotherapy of cancer</i> 8(1) –. DOI:<a href=&quot;https://doi.org/10.1136/jitc-2019-000437&quot;>10.1136/jitc-2019-000437</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32561638/&quot;>https://pubmed.ncbi.nlm.nih.gov/32561638</a></p></li><li><p>Budha, N, et al., &amp; Sahasranaman, S (2023). Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 12(1) 95–109. DOI:<a href=&quot;https://doi.org/10.1002/psp4.12880&quot;>10.1002/psp4.12880</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36330700/&quot;>https://pubmed.ncbi.nlm.nih.gov/36330700</a></p></li><li><p>Desai, J, et al., &amp; Millward, M (2020). Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. <i>Journal for immunotherapy of cancer</i> 8(1) –. DOI:<a href=&quot;https://doi.org/10.1136/jitc-2019-000453&quot;>10.1136/jitc-2019-000453</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32540858/&quot;>https://pubmed.ncbi.nlm.nih.gov/32540858</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FF09;
